Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Kelly A Johnson; Xin Niu; David V Glidden; Jose R Castillo-Mancilla; Jenna Yager; Samantha MaWhinney; Mary Morrow; Hideaki Okochi; Tim R Cressey; Paul K Drain; Monica Gandhi; Peter L Anderson; Matthew A Spinelli

doi:10.1093/ofid/ofab200

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Open Forum Infect Dis. 2021 Apr 17;8(7):ofab200. doi: 10.1093/ofid/ofab200. eCollection 2021 Jul.

Authors

Affiliations

¹ Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
² Department of Epidemiology, University of Washington, Seattle, Washington, USA.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
⁴ University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
⁵ Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
⁶ Institut de Recherche pour le Développement-PHPT Research Unit, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
⁷ Departments of Global Health and Medicine, University of Washington, Seattle, Washington, USA.

Abstract

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.

Keywords: directly observed therapy; pharmacokinetics; point-of-care adherence monitoring; tenofovir alafenamide; tenofovir disoproxil fumarate.

Abstract

Grants and funding